NDAORALTABLETPriority Review
Approved
Aug 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKEEGA is a fixed-dose oral combination of niraparib (a PARP inhibitor) and abiraterone acetate (an androgen synthesis inhibitor) approved in August 2023. It is indicated for metastatic castration-resistant prostate cancer (mCRPC) in patients with homologous recombination repair (HRR) gene mutations. The combination targets dual pathways: DNA repair inhibition and androgen receptor signaling suppression.
$0.567MPart D
GrowthGrowing
11.6 years to LOEEarly-stage growth phase with modest initial uptake (31 Part D claims in 2023) suggests expanding sales team, medical affairs, and reimbursement roles as market penetration accelerates.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Prostate NeoplasmsGenital Neoplasms, MaleUrogenital Neoplasms+1 more
Career Relevance
AKEEGA career opportunities span commercial launch, medical education, and market access roles critical to establishing footprint in precision-medicine mCRPC segment. Early growth phase (2023 approval, 31 claims) indicates ramping sales infrastructure, clinical support expansion, and reimbursement strategy development.
Brand Manager
Worked on AKEEGA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.